Reconstructing dynamic regulatory maps

por Ernst, Jason, Vainas, Oded, Harbison, Christopher T, Simon, Itamar, Bar-Joseph, Ziv
Publicado 2007

An open label randomized Phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-naïve stage IV or recurren...

por Hellmann, Matthew, Ramalingam, Suresh, Reck, Martin, O'Byrne, Ken, Paz-Ares, Luis, Harbison, Christopher T, Bhagavatheeswaran, Prabhu, Nathan, Faith, Brahmer, Julie
Publicado 2015

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer

por Janjigian, Yelena Y., Bendell, Johanna, Calvo, Emiliano, Kim, Joseph W., Ascierto, Paolo A., Sharma, Padmanee, Ott, Patrick A., Peltola, Katriina, Jaeger, Dirk, Evans, Jeffry, de Braud, Filippo, Chau, Ian, Harbison, Christopher T., Dorange, Cecile, Tschaika, Marina, Le, Dung T.
Publicado 2018

Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab

por Topalian, Suzanne L., Hodi, F. Stephen, Brahmer, Julie R., Gettinger, Scott N., Smith, David C., McDermott, David F., Powderly, John D., Sosman, Jeffrey A., Atkins, Michael B., Leming, Philip D., Spigel, David R., Antonia, Scott J., Drilon, Alexander, Wolchok, Jedd D., Carvajal, Richard D., McHenry, M. Brent, Hosein, Fareeda, Harbison, Christopher T., Grosso, Joseph F., Sznol, Mario
Publicado 2019